Disclaimer
This website is provided merely as information and is not intended to be, nor should it be construed as, an offer to sell or a solicitation of an offer to buy any security. This website does not recommend the purchase or sale of any security.
This website is not intended to be, nor should it be construed or used as, investment, tax or legal advice. This website is the exclusive property of AIM ImmunoTech Inc. (the “Company”) and may not be reproduced or distributed, in whole or in part, without the express prior written consent of the Company.
Important Additional Information
The Company, its directors and executive officers, Peter W. Rodino, III and Robert Dickey, IV, are deemed to be “participants” (as defined in Section 14(a) of the Securities Exchange Act of1934, as amended) in the solicitation of proxies from the Company’s stockholders in connection with the Company’s 2024 Annual Meeting of Stockholders (the “Annual Meeting”). The Company filed its definitive proxy statement (the “Definitive Proxy Statement”) and a WHITE universal proxy card with the U.S. Securities and Exchange Commission (the “SEC”) on November 4, 2024 in connection with such solicitation of proxies from the Company’s stockholders. STOCKHOLDERSOF THE COMPANY ARE STRONGLY ENCOURAGED TO READ SUCH DEFINITIVE PROXY STATEMENT,ACCOMPANYING WHITE UNIVERSAL PROXY CARD AND ALL OTHER DOCUMENTS FILEDWITH THE SEC CAREFULLY AND IN THEIR ENTIRETY AS THEY CONTAIN IMPORTANTINFORMATION ABOUT THE ANNUAL MEETING. The Definitive Proxy Statement contains information regarding the identity of the participants, and their direct and indirect interests, by security holdings or otherwise, in the Company’s securities and can be found in the section titled “Principal Stockholders” of the Definitive Proxy Statement and available here. Information regarding subsequent changes to their holdings of the Company’s securities can be found in the SEC filings on Forms 3, 4, and 5, which are available on the Company’s website available here or through the SEC’s website at www.sec.gov. Stockholders will be able to obtain the Definitive Proxy Statement, any amendments or supplements thereto and other documents filed by the Company with the SEC at no charge at the SEC’s website at www.sec.gov. Copies will also be available at no charge at the Company’s website at https://aimimmuno.com/sec-filings/.
Cautionary Statement
The timing of these postings are made at the discretion of the Company. Readers should not assume that the information contained on this website has been updated or otherwise contains current information. The Company does not review past postings to determine whether they remain accurate, and information contained in such postings may have been superseded.
This website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,”
“anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date does not guarantee that Ampligen will be approved as a therapy for endometriosis or ovarian cancer. The Company urges investors to consider specifically the various risk factors identified in its most recent Annual Report on Form 10-K, and any risk factors or cautionary statements included in any subsequent Quarterly Report on Form 10-Q or Current Report on Form 8-K,filed with the SEC, and as described in the press releases and other materials contained on this website. You are cautioned not to place undue reliance on these forward-looking statements. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect new events or circumstances, except as required by federal securities laws.
Testimonials, Other Quotations and Third-Party Statements
This website may contain or refer to news, commentary and other information relating to the Company generated by, or sourced from, persons or companies that are not affiliated with the Company. The Company has neither sought nor obtained consent from any other third party to use any statements or information contained herein that have been obtained or derived from statements made or published by such third parties, including, without limitation, information generated by Ted D. Kellner, Robert L. Chioini, Todd Deutsch and Paul W. Sweeney (collectively, the “Dissident Group”). The Company has not assisted in the preparation of any third party information, including, without limitation, information generated by the Dissident Group. Any statement or information that is obtained or derived from statements made or published by a third party should not be viewed as indicating the support of such third party for any view expressed on this website.
This website may contain links to articles and/or videos (collectively, “Media”). The views and opinions expressed in such Media or those of the author(s)/speaker(s) referenced or quoted in such Media, unless specifically noted otherwise, do not necessarily represent the opinions of the Company.
By clicking “I AGREE” below, I confirm that I have read all of the above.
I Agree
For Investors
JTC Team, LLC
Jenene Thomas
833-475-8247
AIM@jtcir.com
For Media
Longacre SquarePartners
Joe Germani / MillerWinston
AIM@longacresquare.com
If you have any questions or require any assistance in voting your shares, please contact our proxy solicitor:
Sodali & Co.
430 Park Avenue, 14th Floor
New York, NY 10022
Shareholders may call toll-free:
(800) 662-5200
Banks, Brokers, Trustees, and Other Nominees Call Collect:
(203) 658-9400
Email:
AIM@investor.Sodali.com
Anonymously submit your views or concerns using the below form. Note that your personal information will not be saved.
Our Commitment to Privacy
The sponsor of this website, www.SafeguardAIM.com, is AIM ImmunoTech Inc. (the “Sponsor”). We respect and value your privacy. This Privacy Policy is designed to assist you in understanding what information is collected from or about you through this website and how we use and safeguard that information, as well as to assist you in making informed decisions when using the website.
The core of our Privacy Policy is this:
We want you to feel safe and comfortable when you use the website, and we are dedicated to developing and upholding high standards for protecting your privacy. You should read and familiarize yourself with this Privacy Policy and with our Terms and Conditions. If you do not agree with our policies and practices, your choice is not to use this website. By accessing or using this website, you agree to this Privacy Policy.
WHAT INFORMATION DO WE COLLECT?
Our website does not ask you to provide any personally identifiable information. Instead, this website only collects “clickstream data” that provides information about the type of device and browser you are using, and the website from which you linked to our website. We may collect this data via “cookies” or other, similar technologies. For more information about cookies, visit http://www.allaboutcookies.org/.
We may use this data in an aggregate, non-personally identifiable way to help us analyze and answer questions like how much time visitors spend on each page of this website, how visitors navigate throughout this website and how we may tailor our web pages to better meet the needs of visitors. This information will be used to improve this website.
DO WE DISCLOSE INFORMATION TO OUTSIDE PARTIES?
We may provide aggregate information to our affiliates or reputable third parties for the purposes described herein.
WHAT ABOUT LEGALLY COMPELLED DISCLOSURE OF INFORMATION?
We may disclose information when we, in good faith, believe that the law requires it or for the protection of our legal rights.
WHAT ABOUT OTHER WEBSITES LINKED TO OUR SITE?
We are not responsible for the practices employed by websites linked to or from this website nor the information or content contained therein. Often links to other websites are provided solely as pointers to information on topics that may be useful to the users of our website. Please remember that your browsing and interaction on any other website, including websites which have a link on this website, is subject to that website’s own rules and policies. Please review those rules and policies.
CHANGES TO THIS POLICY
We reserve the right to make changes to this Privacy Policy from time to time. Revisions will be posted on this page. We suggest you check this page occasionally for updates. Any continued use of this website after the effective date of any modification to the Privacy Policy will be deemed to be an agreement to the modified terms.
PRIVACY OF CHILDREN
This website is not intended for children under 13 years of age. No one under age 13 may provide any personal information to or on this website. We do not knowingly collect personal information from children under 13. If you are under 13, do not use or provide any information on this website or on or through any of its features/register on this website, use any of the interactive or public comment features of this website, or provide any information about yourself to us, including your name, address, telephone number, email address, or any screen name or user name you may use. If we learn we have collected or received personal information from a child under 13 without verification of parental consent, we will delete that information. If you believe we might have any information from or about a child under 13, please contact us at aim@longacresquare.com.
CONTACTING US
If you have any questions about this Privacy Policy, the practices of this website, or your dealings with this website, you can contact aim@longacresquare.com.
Persons who access the information made available by AIM ImmunoTech Inc. (together with its affiliates, “AIM” or “we” or “us”) via this website (this “website”) agree to the following:
While the material on this website is often about investments, none of it is offered as investment advice. For members of the public, this means that neither the receipt nor the distribution of information through this website constitutes the formation of an investment advisory relationship, or any similar client relationship. The materials on this website are for informational purposes only and may not be relied on by any person for any purpose and are not, and should not be construed as investment, financial, legal, tax or other advice, recommendation or research.
This website contains hyperlinks to websites operated by AIM and other parties. AIM does not control the content or accuracy of information on third-party websites and does not otherwise endorse the material placed on such sites.
All information and content on this website is furnished “AS IS,” without warranty of any kind, express or implied. AIM will not assume any liability for any loss or damage of any kind arising, whether direct or indirect, caused by the use of any part of the information provided. AIM and its licensors do not warrant that the content is accurate, reliable or correct; that the website will be available at any particular time or location; that any defects or errors will be corrected; that unauthorized access to or misappropriation of the content will not occur; or that the content is free of viruses or other harmful components. Your use of this website is solely at your risk.
The entire website is subject to copyright with all rights reserved. No permission is granted to copy, distribute, modify, post or frame any text, graphics, video, audio, software code, or user interface design or logos. The information contained herein shall not be published, rewritten for broadcast or publication or redistributed in any medium without prior written permission from AIM.